The Drug-Specific Propensity Regarding the Acquisition of Fluoroquinolone Resistance in Escherichia coli: An in vitro Challenge and DNA Mutation Analysis

被引:0
作者
Sato, Takumi [1 ,3 ]
Ito, Ryota [1 ,2 ]
Kawamura, Masato [1 ]
Fujimura, Shigeru [1 ]
机构
[1] Tohoku Med & Pharmaceut Univ, Div Clin Infect Dis & Chemotherapy, Sendai, Japan
[2] Japan Lab Hlth & Welf Org Tohoku Rosai Hosp, Dept Pharm, Sendai, Japan
[3] Tohoku Med & Pharmaceut Univ, Div Clin Infect Dis & Chemotherapy, 4-4-1 Komatsushima,Aoba Ku, Sendai 9818558, Japan
关键词
Escherichia coli; respiratory quinolone; mutant selection window; quinolone-resistance determining region; efflux pump; QUINOLONE RESISTANCE; PHARMACOKINETICS; EMERGENCE; CIPROFLOXACIN; BMS-284756; PNEUMONIA; INFECTION; SINGLE;
D O I
10.2147/IDR.S428383
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Many fluoroquinolones, such as ciprofloxacin, are used clinically. We investigated the relationship between resistance acquisition and exposure duration in each drug through the exposure of fluoroquinolone to Escherichia coli clinical isolates in vitro.Methods: Eleven E. coli clinical isolates were exposed to each fluoroquinolone, ie, ciprofloxacin, levofloxacin, sitafloxacin, garenoxacin, and lascufloxacin, with the concentration of the mutant selection window for 5 days; these procedures were repeated 5-times. In addition, the DNA sequence in the quinolone-resistance determining region (QRDR) and the expression level in the drug efflux pump acrA were analyzed to determine the resistance mechanism.Results: Although resistant strains were not detected after 5 to 10 days of exposure to fluoroquinolone, after 25 days of exposure to ciprofloxacin and levofloxacin, 100% and 45% of isolates acquired resistance, respectively. Due to 25 days of exposure to sitafloxacin, garenoxacin, and lascufloxacin, MIC measurement was elevated 2-to 4096-fold for those of the parental strain, and the cross-resistance rate to levofloxacin was 72%, 54%, and 27%, respectively. In strains with high fluoroquinolone resistance, acrA over-expression was observed in addition to QRDR mutation. Conclusion: In our findings, fluoroquinolone resistance was not observed in the E. coli strain after 5-to 10-days of exposure. However, resistance acquisition was detected frequently after 15-to 25-days of exposure. Among fluoroquinolones, lascufloxacn had the least impact on the resistance acquisition in E. coli. Plain LanguageSummary: The need to combat quinolone-resistant E. coli is urgent. The resistance acquisition tendency of E. coli varies according to the drug used. After 25 days of exposure, 45% of E. coli showed levofloxacin resistance. Lascufloxacin may have the lowest influence on resistance acquisition to regular E. coli.
引用
收藏
页码:6357 / 6366
页数:10
相关论文
共 35 条
[1]   Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013-18): a quasi-experimental, ecological, data linkage study [J].
Aliabadi, Shirin ;
Anyanwu, Philip ;
Beech, Elizabeth ;
Jauneikaite, Elita ;
Wilson, Peter ;
Hope, Russell ;
Majeed, Azeem ;
Muller-Pebody, Berit ;
Costelloe, Ceire .
LANCET INFECTIOUS DISEASES, 2021, 21 (12) :1689-1700
[2]  
[Anonymous], 2016, Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, V3rd
[3]   The Role of AcrAB-TolC Efflux Pumps on Quinolone Resistance of E-coli ST131 [J].
Atac, N. ;
Kurt-Azap, O. ;
Dolapci, I. ;
Yesilkaya, A. ;
Ergonul, O. ;
Gonen, M. ;
Can, F. .
CURRENT MICROBIOLOGY, 2018, 75 (12) :1661-1666
[4]   Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin [J].
Bergallo, Carlos ;
Jasovich, Abet ;
Teglia, Osvaldo ;
Eugenia Oliva, Maria ;
Lentnek, Arnold ;
de Wouters, Luisa ;
Zlocowski, Juan Carlos ;
Dukart, Gary ;
Cooper, Angel ;
Mallick, Rajiv .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (01) :52-61
[5]  
Clinical and Laboratory Standards Institute, 2020, CLSI supplement
[6]   Resistance among urinary tract pathogens collected in Europe during 2018 [J].
Critchley, Ian A. ;
Cotroneo, Nicole ;
Pucci, Michael J. ;
Jain, Akash ;
Mendes, Rodrigo E. .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 23 :439-444
[7]   Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone [J].
de Lastours, Victoire ;
Chau, Francoise ;
Roy, Carine ;
Larroque, Beatrice ;
Fantin, Bruno .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) :3393-3400
[8]   Community-Associated Extended-Spectrum β-Lactamase-Producing Escherichia coli Infection in the United States [J].
Doi, Yohei ;
Park, Yoon Soo ;
Rivera, Jesabel I. ;
Adams-Haduch, Jennifer M. ;
Hingwe, Ameet ;
Sordillo, Emilia M. ;
Lewis, James S., II ;
Howard, Wanita J. ;
Johnson, Laura E. ;
Polsky, Bruce ;
Jorgensen, James H. ;
Richter, Sandra S. ;
Shutt, Kathleen A. ;
Paterson, David L. .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (05) :641-648
[9]   Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria [J].
Fantin, Bruno ;
Duval, Xavier ;
Massias, Laurent ;
Alavoine, Loubna ;
Chau, Francoise ;
Retout, Sylvie ;
Andremont, Antoine ;
Mentre, France .
JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (03) :390-398
[10]   The clinical pharmacokinetics of levofloxacin [J].
Fish, DN ;
Chow, AT .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :101-119